ArticleBulletin of experimental biology and medicine2025
A Novel Bacteriophage Targeting Adherent-Invasive Escherichia coli: A Potential Therapeutic Agent for Crohn's Disease.
Article in Bulletin of experimental biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global spread of multidrug-resistant pathogens underscores the urgent need for novel therapeutic strategies against bacterial infections. One promising approach is phage therapy, which utilizes lytic bacteriophages that exhibit high specificity for their bacterial hosts. In this study, we isolated a novel bacteriophage, vB_EcoA_PHZVL, belonging to the family Autographiviridae, which demonstrates potent lytic activity against a clinical strain of adherent-invasive Escherichia coli (AIEC) isolated from a patient with Crohn's disease (CD). We further demonstrated that both plaque morphology and phage adsorption efficiency are influenced by the composition of the culture medium and the carbon source, likely due to alterations in LPS structure on the bacterial surface. These findings enhance our understanding of phage-host interactions and highlight the potential of vB_EcoA_PHZVL as a candidate for phage-based therapy in CD.
Indexed as
Identifiers
41665752What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.